B+
Bull case
30%
Probability
Target price
$5.00
+15.2% vs current
CCCC
C4 TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$3.10
-28.6% vs current
B-
Bear case
25%
Probability
Target price
$1.70
-60.8% vs current
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+24.9
Score
AI commentary
Lean monitoring view. Recent primary-source news flow is constructive, especially the April 9, 2026 Roche collaboration and March 25, 2026 first-patient dosing in the elranatamab combination study, but this T+3 earnings follow-up did not uncover a company Q1 2026 earnings release, 8-K results filing, or 10-Q as of May 8, 2026, so post-print surprise, estimate revision, and target-change evidence remain unavailable. That keeps the thesis close to the deterministic prior: thesis_change_score improved to 0.685 and expected returns turned modestly positive, but evidence_quality_score is still only 0.54 and uncertainty remains elevated at 0.588. With thin coverage and no fresh quarterly filing, the setup stays neutral-to-watch rather than upgraded.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-15catalystMid-2026 additional cemsidomide Phase 1 analysisHigh impact
Management said it plans to present further analysis from the completed Phase 1 cemsidomide plus dexamethasone study in mid-2026, which remains the nearest efficacy and safety checkpoint for the lead multiple myeloma program and the clearest near-term test of whether the differentiated profile holds as development moves later stage [#10-K-2026-02-26] [#EX-99.1-2026-02-26].
2026-09-30eventElranatamab combination progress after first-patient dosingHigh impact
C4T announced first-patient dosing in the Phase 1b cemsidomide plus elranatamab study on March 25, 2026, and had guided to provide incremental progress through 2026. Clean dose-escalation and enrollment progress would help support the earlier-line myeloma strategy, but this remains an early execution checkpoint rather than a de-risked efficacy readout [#PR-2026-03-25] [#EX-99.1-2026-02-26].
2026-12-31catalystRoche degrader-antibody conjugate collaboration executionHigh impact
The April 9, 2026 Roche agreement adds a $20 million upfront payment plus large downstream milestone optionality, giving C4T a non-cemsidomide value lever and some funding support. The stock is unlikely to capitalize much of that headline value until investors see concrete research-stage progress or clearer cash-runway benefit from the collaboration economics [#8-K-2026-04-09].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology